Insmed, Inc.
INSM
$107.15
-1.82%
Insmed, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, operating within the Biotechnology industry. The company has established a distinct competitive identity as a commercial-stage player with a specialized focus on respiratory diseases, anchored by its two marketed products, Arikayce and Brinsupri, while advancing a diverse clinical pipeline across immunology, inflammation, and neuro-rare conditions. The current investor narrative is dominated by the company's commercial execution and the progression of its pipeline, particularly the clinical-stage programs like brensocatib and INS1201, which represent significant future growth catalysts, though recent stock price volatility suggests ongoing debate about the path to profitability and the valuation of its pipeline assets.…
INSM
Insmed, Inc.
$107.15
Related headlines
Investment Opinion: Should I buy INSM Today?
Rating: Hold. The core thesis is that while INSM possesses a compelling long-term growth narrative backed by analyst conviction, its extreme valuation, profound near-term losses, and broken technical picture create an unacceptable level of risk for new capital at the current price.
Supporting this Hold rating are several data points: the stratospheric 61.3x PS ratio versus industry norms, the widening Q4 net loss of -$328.5 million, the negative TTM free cash flow of -$997.6 million, and the stock's severe underperformance (-31.2% vs. SPY over one month). Analyst bullishness and 152.6% revenue growth are positive, but they are already richly priced in, leaving minimal margin for error.
The thesis would upgrade to a Buy if the stock's valuation compresses significantly (e.g., PS ratio falling towards 30x on sustained commercial growth) or if a major clinical catalyst (like positive pivotal data for brensocatib) de-risks the pipeline without requiring further dilution. It would downgrade to a Sell if quarterly revenue growth decelerates sharply below 50%, if the cash burn rate accelerates, or if the stock breaks decisively below its 52-week low of $64.85. Based on current data, the stock is overvalued relative to its present financials but may be fairly valued only if one fully believes in the multi-billion dollar revenue forecasts years into the future.
Sign up to view all
INSM 12-Month Price Forecast
INSM is a binary, high-risk/high-reward story caught between a promising future and a perilous present. The neutral stance reflects the offsetting forces of explosive growth potential against an unsustainable financial model and extreme valuation. Confidence is medium because the near-term path is highly dependent on unpredictable clinical data and financing markets. The stance would upgrade to bullish only on concrete evidence of pipeline de-risking combined with a more reasonable valuation entry point. It would turn bearish on any material commercial slowdown or clinical failure, which could trigger a downward spiral given the fragile financial position.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $139.30 and implied upside of +30.0% versus the current price.
Average Target
$139.30
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$86 - $139
Analyst target range
Eight analysts cover the stock, and recent institutional ratings show a pattern of reiterated bullish stances, with firms like Morgan Stanley upgrading to 'Overweight' and others such as Wells Fargo and B of A Securities maintaining 'Buy' or equivalent ratings in March 2026. While a specific consensus price target is not provided in the data, the analyst revenue estimates imply a significant growth trajectory, with an average estimate of $6.31 billion for the forecast period, ranging from a low of $5.57 billion to a high of $6.97 billion, indicating strong conviction in the commercial potential but also a wide spread that reflects underlying uncertainty. The pattern of recent analyst actions, all being reiterations or upgrades, signals maintained institutional confidence in the company's long-term story despite the severe technical breakdown, though the lack of a quantified price target range limits the precision of the implied upside calculation from the current price of $109.14.
Bulls vs Bears: INSM Investment Factors
The evidence currently tilts bearish, primarily due to the extreme valuation disconnect from near-term financial reality. The bull case is compelling but entirely forward-looking, hinging on the flawless execution of a multi-year plan to grow revenue nearly tenfold. The bear case is grounded in present metrics: catastrophic losses, heavy cash burn, and a stock price that has already broken down technically. The single most important tension in the investment debate is whether the company's clinical pipeline can deliver the blockbuster outcomes necessary to justify its 61x sales multiple before its financial runway expires. The resolution of this binary, high-risk/high-reward pipeline data will determine the stock's fate.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $263.8 million grew 152.6% YoY and more than doubled sequentially from Q3. This demonstrates strong commercial execution for its marketed products, Arikayce and Brinsupri, and validates the underlying demand.
- High Gross Margin Profile: The company maintains a robust gross margin of 82.5% (Q4 2025), which is characteristic of a successful biopharmaceutical business model. This provides a strong foundation for future profitability if operating expenses can be controlled as sales scale.
- Analyst Confidence in Long-Term Story: All eight covering analysts have reiterated or upgraded to bullish ratings (e.g., Morgan Stanley to Overweight) in March 2026, signaling sustained institutional conviction despite the stock's severe technical breakdown. Their average revenue estimate of $6.31 billion implies massive future growth from the current ~$690 million run-rate.
- Diverse Clinical Pipeline Catalysts: The company has multiple clinical-stage programs (brensocatib, INS1201, etc.) across immunology and rare diseases. Successful development of these assets represents significant, non-dilutive future value drivers that are not reflected in current commercial revenue.
Bearish
- Extreme Valuation Premium: The stock trades at a stratospheric trailing Price-to-Sales (PS) ratio of 61.3x, far above typical biotech industry averages. This leaves absolutely no margin for error and prices in near-perfect execution of its entire pipeline to reach multi-billion dollar revenues.
- Massive and Widening Losses: The company is deeply unprofitable, with a Q4 2025 net loss of $328.5 million, which widened from $235.5 million a year prior. The trailing twelve-month free cash flow is -$997.6 million, indicating a severe cash burn that necessitates future dilutive financing.
- Severe Technical Breakdown: The stock is in a pronounced downtrend, down 43.5% over six months and 38.4% YTD. It has underperformed the S&P 500 by over 31% in the past month, indicating a complete loss of momentum and a breakdown from its previous uptrend.
- High Financial Leverage and Risk: With a debt-to-equity ratio of 1.04 and a negative Return on Equity of -172.8%, the company's capital structure is leveraged while generating no returns for equity holders. This amplifies risk if revenue growth falters or financing conditions tighten.
INSM Technical Analysis
The stock is in a pronounced downtrend, having declined 43.5% over the past six months and 38.4% year-to-date as of the analysis date. With a current price of $109.14, the stock is trading approximately 51% above its 52-week low of $64.85 but 49% below its 52-week high of $212.75, positioning it in the lower half of its annual range and indicating significant pressure and a loss of momentum from previous highs. Recent momentum is decisively negative and diverges sharply from the positive 1-year return of 62.4%, with the stock down 25.6% over the past month and 26.6% over the past three months, a stark reversal that signals a breakdown in the longer-term uptrend, exacerbated by a relative strength reading of -31.2 versus the S&P 500 over the same period. Key technical support is clearly defined at the 52-week low of $64.85, while resistance sits at the recent breakdown level near the 52-week high of $212.75; a sustained break below support would signal a continuation of the bearish trend, while the stock's beta of 0.89 indicates its volatility is slightly below the broader market, though this has not insulated it from severe recent declines.
Beta
0.89
0.89x market volatility
Max Drawdown
-52.1%
Largest decline past year
52-Week Range
$65-$213
Price range past year
Annual Return
+57.3%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | -25.8% | +4.0% |
| 3m | -28.8% | +8.2% |
| 6m | -47.4% | +11.5% |
| 1y | +57.3% | +24.3% |
| ytd | -39.5% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Revenue is growing but at a decelerating pace, with Q4 2025 revenue of $263.8 million representing a 152.6% year-over-year increase, though this explosive growth is partly due to a low base effect from the prior year's $104.4 million; sequentially, revenue more than doubled from Q3's $142.3 million, indicating strong quarterly execution for its commercial products. The company remains deeply unprofitable, reporting a net loss of $328.5 million in Q4 2025, with a gross margin of 82.5% that is healthy for a biotech but overshadowed by massive operating expenses; the net loss widened from $235.5 million in Q4 2024, and the trailing twelve-month free cash flow is deeply negative at -$997.6 million, highlighting the cash burn required to fund growth and R&D. The balance sheet shows a debt-to-equity ratio of 1.04, indicating a leveraged capital structure, while the current ratio of 3.83 suggests sufficient short-term liquidity; however, the negative return on equity of -172.8% and negative free cash flow underscore the significant financial risk and the company's dependence on external financing to sustain its operations and pipeline development.
Quarterly Revenue
$263843000.0B
2025-12
Revenue YoY Growth
+1.52%
YoY Comparison
Gross Margin
+0.82%
Latest Quarter
Free Cash Flow
$-997575000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Given the consistently negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is an extremely high 61.3x, while the forward-looking EV/Sales multiple is 30.0x; the significant gap between these multiples suggests the market is pricing in substantial future revenue growth, as analyst consensus estimates project revenue to reach approximately $6.3 billion, a massive increase from current levels. Compared to typical biotechnology industry averages, which often range in the mid-to-high single digits for PS ratios, Insmed's 61.3x multiple represents a stratospheric premium, which would only be justified by blockbuster commercial success and flawless execution of its clinical pipeline to drive revenue towards the multi-billion dollar estimates. Historically, the stock's own PS ratio has been volatile but consistently elevated, with a reading of 140.9x as of Q4 2025; the current 61.3x, while lower, remains near the upper end of its historical range, indicating that despite the recent price collapse, the market is still embedding high expectations for future sales, leaving little margin for error.
PE
-29.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company is burning cash at an alarming rate, with TTM free cash flow of -$997.6 million and a Q4 2025 net loss of -$328.5 million. With a debt-to-equity ratio of 1.04, it is leveraged while generating negative returns (ROE: -172.8%). Revenue, while growing explosively at 152.6% YoY in Q4, is still only at a ~$690 million annual run-rate, meaning the company is far from self-sufficiency and remains entirely dependent on external capital markets to fund its operations and ambitious R&D pipeline. Any hiccup in commercial execution or delay in pipeline development could trigger a liquidity crisis.
Market & Competitive Risks center on valuation compression. Trading at a PS ratio of 61.3x, INSM carries a premium that assumes flawless success. If growth decelerates or clinical trials disappoint, a severe multiple contraction is likely. The stock's beta of 0.89 suggests it is slightly less volatile than the market, but this has not prevented a 43.5% six-month decline, indicating company-specific risk dominates. Competitive threats in its core respiratory and rare disease markets could erode pricing power for its commercial products, while a broader sector rotation away from high-multiple, pre-profitability biotech stocks presents a macro headwind.
Worst-Case Scenario involves a combination of a clinical pipeline setback (e.g., a failed Phase 3 trial for brensocatib), slower-than-expected commercial uptake, and a tightening financing environment. This could lead to a liquidity crunch, forcing a highly dilutive equity offering at a depressed price. Investor sentiment would collapse, driving a re-rating towards a more typical, yet still punitive, biotech PS multiple for a struggling company. The realistic downside could see the stock retest its 52-week low of $64.85, representing a potential loss of approximately -41% from the current price of $109.14.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The company is burning over $1 billion annually in free cash flow with significant debt (D/E: 1.04), risking a liquidity crisis or highly dilutive financing. 2) Valuation Risk: The 61.3x PS ratio leaves no room for error; any growth slowdown or pipeline setback could trigger a catastrophic multiple contraction. 3) Clinical & Pipeline Risk: The future value is tied to unproven clinical-stage assets like brensocatib; trial failures would destroy significant equity value. 4) Execution Risk: The company must rapidly scale commercial revenue from ~$690M to over $6B to justify its valuation, a highly challenging task.
The 12-month forecast is highly bifurcated, with a 50% probability Base Case target range of $100-$150, a 25% probability Bull Case range of $180-$212, and a 25% probability Bear Case range of $65-$95. The Base Case, which is most likely, assumes continued commercial growth but no major pipeline breakthroughs, keeping the stock volatile and range-bound. The forecast hinges almost entirely on the company's ability to deliver on its commercial promise and advance its clinical pipeline without major setbacks. The wide spread in targets reflects the extreme uncertainty and binary nature of the underlying assets.
INSM is dramatically overvalued based on conventional metrics applied to its current financials. A trailing PS ratio of 61.3x is stratospheric compared to the biotech industry and is only justified if the company achieves analyst revenue estimates of ~$6.3 billion, a nearly tenfold increase. The forward EV/Sales of 30.0x is also very high. The market is pricing in near-perfect execution of its entire pipeline years in advance. Therefore, based on present earnings (-$328.5M net loss) and cash flow, the stock is overvalued. It could be considered fairly valued only if one fully discounts the future multi-billion dollar revenue stream as a near certainty.
INSM is not a good buy for most investors at its current price of $109.14. While analyst targets imply significant upside, the stock carries extreme risk due to its 61.3x Price-to-Sales multiple, -$997.6 million in trailing free cash flow burn, and severe technical downtrend (-43.5% over six months). It could be a speculative buy only for highly risk-tolerant investors who have deep conviction in its clinical pipeline and are prepared to withstand further volatility and potential dilution. For others, it is a Hold; waiting for a lower entry point or de-risking clinical data is prudent.
INSM is strictly a long-term, speculative investment with a minimum horizon of 3-5 years. The company is years away from potential profitability, and its value will be determined by the success of clinical trials and commercial ramp-up that will unfold over many quarters. Its high beta (0.89) and recent extreme volatility (-25.6% in one month) make it unsuitable for short-term trading, as price swings can be severe and driven by binary news flow. Only investors with the patience and risk tolerance to wait for the pipeline to mature should consider it.
